Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer

[1]  M. Bernadet,et al.  Prolactin receptor antagonism in mouse anterior pituitary: effects on cell turnover and prolactin receptor expression. , 2012, American journal of physiology. Endocrinology and metabolism.

[2]  Jing Jiang,et al.  Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. , 2011, Molecular endocrinology.

[3]  M. Berchtold,et al.  Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. , 2010, Endocrine-related cancer.

[4]  A. Walker,et al.  Short form 1b human prolactin receptor down-regulates expression of the long form. , 2010, Journal of molecular endocrinology.

[5]  H. Rui,et al.  Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. , 2009, The Journal of endocrinology.

[6]  B. Rasmussen,et al.  Re-evaluation of the prolactin receptor expression in human breast cancer. , 2009, The Journal of endocrinology.

[7]  H. Rui,et al.  Impaired turnover of prolactin receptor contributes to transformation of human breast cells. , 2009, Cancer research.

[8]  A. Zambrano,et al.  Activation of the unliganded estrogen receptor by prolactin in breast cancer cells , 2009, Oncogene.

[9]  R. Clarke,et al.  Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity , 2008, Breast Cancer Research.

[10]  Leif Christensen,et al.  Crystal Structure of a Prolactin Receptor Antagonist Bound to the Extracellular Domain of the Prolactin Receptor* , 2008, Journal of Biological Chemistry.

[11]  John E Tomaszewski,et al.  Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma , 2008, Modern Pathology.

[12]  S. Hankinson,et al.  Prolactin and Breast Cancer Etiology: An Epidemiologic Perspective , 2008, Journal of Mammary Gland Biology and Neoplasia.

[13]  S. Fuchs,et al.  Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. , 2008, The Journal of endocrinology.

[14]  L. Schuler,et al.  Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context , 2007, Oncogene.

[15]  F G Robertson,et al.  Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions , 2007, Oncogene.

[16]  S. Gadd,et al.  Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. , 2006, Molecular endocrinology.

[17]  P. Kelly,et al.  Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. , 2006, The Journal of endocrinology.

[18]  Lothar Hennighausen,et al.  Information networks in the mammary gland , 2005, Nature Reviews Molecular Cell Biology.

[19]  P. Gluckman,et al.  Gene Expression Profiling to Identify Oncogenic Determinants of Autocrine Human Growth Hormone in Human Mammary Carcinoma* , 2005, Journal of Biological Chemistry.

[20]  Wen Y. Chen,et al.  Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice , 2004, Oncogene.

[21]  L. Schuler,et al.  Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor α and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  R. Muñoz,et al.  Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. , 2003, Molecular endocrinology.

[23]  L. Schuler,et al.  Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice , 2003, Oncogene.

[24]  K. Liby,et al.  Prolactin Overexpression by MDA-MB-435 Human Breast Cancer Cells Accelerates Tumor Growth , 2003, Breast Cancer Research and Treatment.

[25]  K. Liby,et al.  Prolactin as an autocrine/paracrine growth factor in human cancer , 2002, Trends in Endocrinology & Metabolism.

[26]  P. Kelly,et al.  Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation , 2000, Oncogene.

[27]  H. Vora,et al.  Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  N. Chen,et al.  A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  C. Ohlsson,et al.  Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. , 1997, The Journal of clinical investigation.

[30]  C. Powell,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression of Prolactin and Its Receptor in Human Breast Carcinoma* , 2022 .

[31]  J. Shull,et al.  Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: Promoter usage and alternative mRNA splicing , 1997, Breast Cancer Research and Treatment.

[32]  N. Ben-Jonathan,et al.  Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. , 1996, Endocrine reviews.

[33]  B. Vonderhaar,et al.  Prolactin synthesis and secretion by human breast cancer cells. , 1995, Cancer research.

[34]  D. L. Sokol,et al.  Vav Is Necessary for Prolactin-stimulated Proliferation and Is Translocated into the Nucleus of a T-cell Line (*) , 1995, The Journal of Biological Chemistry.

[35]  J. Tomaszewski,et al.  Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. , 1995, The American journal of pathology.

[36]  Ivan Dikic,et al.  PC12 cells overexpressing the insulin receptor undergo insulin-dependent neuronal differentiation , 1994, Current Biology.

[37]  P. Cohen,et al.  EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor , 1994, Current Biology.

[38]  R. Lloyd,et al.  Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[39]  A. Mcneilly,et al.  Localization of the sites of synthesis and action of prolactin by immunocytochemistry and in-situ hybridization within the human utero-placental unit. , 1991, Journal of Molecular Endocrinology.

[40]  B. Gellersen,et al.  Prolactin (PRL) mRNA from human decidua differs from pituitary PRL mRNA but resembles the IM-9-P3 lymphoblast PRL transcript , 1989, Molecular and Cellular Endocrinology.

[41]  L. Schuler,et al.  Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. , 2003, Oncogene.

[42]  B. Nielsen,et al.  Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. , 1996, Laboratory investigation; a journal of technical methods and pathology.